Latest News
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
27 November 2025 - Chinese biopharmaceutical company Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced on Thursday that it has begun GRADUAL-3, its third large-scale phase 3 study of the GLP-1 receptor agonist bofanglutide (GZR18) in ov...
Mendus reports trial follow-up data supporting potential of vididencel in high-risk ovarian cancer
27 November 2025 - Swedish biopharmaceutical company Mendus AB (STO:IMMU) on Thursday reported positive two-year follow-up data from the ALISON Phase 1 trial, confirming the safety, tolerability and feasibility of vididencel as an active immunotherap...
Medivir granted FDA orphan drug designation for MIV-711 in osteogenesis imperfecta
27 November 2025 - Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Thursday that its selective cathepsin K inhibitor, MIV-711, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatme...
Novo Nordisk submits sNDA to FDA for for higher semaglutide injection dose
27 November 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Wednesday that it has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for a higher dose of semagl...
Vascular Perfusion Solutions forms collaboration to advance biostasis compounds for organ preservation
27 November 2025 - Vascular Perfusion Solutions Inc (VPS), developer of the VP.S ENCORE platform designed to preserve donor hearts and other organs for extended durations, announced on Wednesday that it has partnered with the Wyss Institute at Harvar...